RATIONALE: The rate of emergency department (ED) visits due to food allergy (FA) reactions including anaphylaxis is increasing, yet in children with FA, the exact rate of accidental FA reactions (AFARs) requiring ED evaluation is not definitively known.
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Patient Attitudes Towards Self-Administered Epinephrine Devices in Subcutaneous Allergen Immunotherapy Anil Nanda, MD FAAAAI Allergy and Asthma Center, Mc Lean, VA. RATIONALE: There is a risk of systemic reactions to allergen immunotherapy. Many allergists/immunologists prescribe self-administered injectable epinephrine devices to patients on allergen immunotherapy. However, there are issues with epinephrine, including cost-issues and patient preferences. We report data on attitudes of patients, who were initiated on allergen immunotherapy, regarding self-administered injectable epinephrine devices. METHODS: A chart review was performed of adult patients at a suburban allergy/immunology practice over an approximate one year period. Patients who were started on subcutaneous allergen immunotherapy were offered self-administered injectable epinephrine devices. Risks and benefits of subcutaneous allergen immunotherapy were discussed as well as the various injectable epinephrine devices available. RESULTS: There were a total of 60 patients. All patients were counseled on a recommended 30 minute wait in a physician supervised office after allergen immunotherapy injections. Forty-five (75%) patients accepted and filled the prescription for the self-administered injectable epinephrine devices. Fifteen patients refused the devices, and the reasons for their refusal were documented. Twelve of these patients did not feel that they needed epinephrine, and three refused based upon cost issues for the devices. CONCLUSIONS: This clinical observation revealed that most patients agreed with carrying epinephrine devices in case there is a systemic reaction to allergen immunotherapy. However, some patients consider these devices unnecessary, and cost can play a role in their refusal. The allergist/immunologist must be aware of the potential financial and other issues involved with epinephrine devices.
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The University Hospital Alexandrovska, Sofia, Bulgaria. RATIONALE: The Network for Online Registration of Anaphylaxis (NORA) is an international platform for anaphylactic reaction documentation. This project aims at standardization of data collection on anaphylaxis triggers, covariates, symptoms and treatment modalities in the participating countries. Bulgaria is a moderate sized European country with specific ethnic, geographic, dietary, socio-economic and healthcare system characteristics possibly reflected in the epidemiology of severe allergic reactions. METHODS: Researchers from 2 centres in the city of Sofia, Alexander's Hospital (children) and Tokuda Hospital (adults), have uploaded cases of patients surviving anaphylactic and severe allergic reactions. Medical reports issued by hospitals and emergency rooms complimented the information provided by patients during live interviews using NORA's standard questionnaire. RESULTS: The number of cases provided by the two Bulgarian centres was 188 (49% male); age range 1 to 73 years with 2 age peaks: 34 (18.1%) were preschool age (1-7 years) and 86 (45.7%) were age 28 to 53 years. Skin symptoms presented in 179 (95.2%), respiratory symptoms in 130 (69.1%), cardiovascular symptoms in 112 (59.6%), typically within 30 minutes of exposure. Triggers of reactions were drugs in 72 (38.3%); food in 63 (33.5%); and insect stings in 20 (10.6%). The place of occurrence was indoors in 111 (59%); medical establishments in 2 (11.7%); outdoors in 20 (10.6%); and at restaurants in 11 (5.8%) subjects. CONCLUSIONS: A remarkable feature of the anaphylaxis morbidity of the patients from the two Bulgarian centres was the large number of druginduced reactions.
